Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

Veltkamp, Stephan A.; Terwogt, Jetske M. Meerum; Heuvel, Michel M. van den; Boven, Hester H. van; Schellens, Jan H.M.; Rodenhuis, S.

doi:10.1007/s10637-006-9030-7

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical picture is also potentially consistent with the pneumonitis-type pulmonary toxicity described with both gemcitabine and docetaxel, thus we considered this event possibly treatment-related. [7][8][9][10][30][31][32][33].…”

Section: Discussionmentioning

confidence: 99%

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Hensley

Blessing

Mannel

et al. 2008

Gynecologic Oncology

286

167

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Hensley

Blessing

Mannel

et al. 2008

Gynecologic Oncology

286

167

View full text Add to dashboard Cite

show abstract

“…Although 50% of patients received at least one red blood cell transfusion, only 20% of patients had grade 3 anemia (hemoglobin < 8 gm/dl), suggesting that the threshold for recommending red cell transfusion was low among treating physicians. Pulmonary toxicity, described as interstitial lung toxicity with dyspnea and hypoxia that may be severe, has been reported with gemcitabine, docetaxel, and with combinations of gemcitabine plus taxanes [30][31][32][33][34]. Although grade 3 pulmonary toxicity was reported in three patients, and grade 4 in one, none of these four patients appears to have had the typical chemotherapy-related interstitial lung toxicity described with gemcitabine plus taxane therapy.…”

Section: Discussionmentioning

confidence: 99%

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Hensley

Blessing

Mannel

et al. 2008

Gynecologic Oncology

251

133

View full text Add to dashboard Cite

Objective-Doxorubicin-based treatment is standard therapy for metastatic uterine leiomyosarcoma. There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma.Methods-Eligible women with unresectable uterine leiomyosarcoma progressing after prior cytotoxic therapy were treated with gemcitabine 900 mg/m 2 days one and eight over 90 minutes, plus docetaxel 100 mg/m 2 on day 8 of a 21-day cycle with granulocyte growth factor. Patients with prior pelvic radiation received lower doses. Response Evaluation Criteria in Solid Tumors (RECIST) response was assessed by computed tomography (CT).Results-Forty-eight of 51 women were evaluable for response (one wrong histology, two never treated). Prior therapy was doxorubicin-based in 90%, and ifosfamide-based in 6%. The overall objective response rate is 27%, with complete response in 6.3% (3/48), and partial response in 20.8% (10/48). An additional 50% (24/48) had stable disease (median duration 5.4 months). The median number of cycles per patient was 5.5 (range 1-22); 73% of patients remained progression-free at 12 weeks and 52% at 24 weeks. The predominant toxicity was uncomplicated myelosuppression: thrombocytopenia grade 3 (29%), grade 4 (10.4%); neutropenia grade 3 (12.5%), grade 4 (8.3%) anemia grade 3 (20.8%), grade 4 (4.2%). While pulmonary toxicity was reported, no patient had drug-related pneumonitis/hypoxia-type toxicity. Median progression-free survival (PFS) was 5. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript months (range 0.7 -27+ months). The median duration of objective response was 9+ months (range 3.9 -24.5+ months).Conclusion-Fixed-dose rate gemcitabine plus docetaxel is active second-line therapy for uterine leiomyosarcoma.

show abstract

“…We reviewed the cases published in the literature [5,8,[10][11][12][13][14][15][16][17][18][19][20][21][22] and the undesirable effects reported from clinical trials with gemcitabine, fi nding that all the analysed patients presented advanced-stage cancer, largely of the lung. In these patients, the drug's intrinsic pulmonary toxicity could be intensifi ed by other factors, such as age, pre-existing chronic lung disease and chest radiotherapy, resulting in a poor evolution of the symptoms.…”

Section: Discussionmentioning

confidence: 99%

Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine

et al. 2010

View full text Add to dashboard Cite

Gemcitabine is indicated for the treatment of nonmicrocytic lung, breast, pancreatic, bladder and ovarian cancer. Mild dyspnea has been reported but the incidence of severe lung damage is low. We report the case of a 58-year-old woman diagnosed with locally advanced infiltrating ductal carcinoma of the breast who received gemcitabine as part of neoadjuvant chemotherapy and suffered from severe pulmonary toxicity. We reviewed the cases published in the literature and conclude that although Gemcitabine is generally well tolerated, pulmonary toxicity requires high level of suspicion and prompt treatment to prevent an unfavourable outcome.

show abstract

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

Cited by 7 publications

References 6 publications

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine

Contact Info

Product

Resources

About